Skip to main contentSkip to navigationSkip to navigation
Harvey Keitel was replaced by Kevin Spacey in a set of ads for E*Trade.
Harvey Keitel was replaced by Kevin Spacey in a set of ads for E*Trade. Photograph: Ian Gavan/Getty Images
Harvey Keitel was replaced by Kevin Spacey in a set of ads for E*Trade. Photograph: Ian Gavan/Getty Images

Harvey Keitel is suing financial company for breach of contract

This article is more than 8 years old

The actor has filed a $1.5m lawsuit against E*Trade for dropping him from an ad campaign and ‘moving in a different direction’ ... with Kevin Spacey

Harvey Keitel is suing financial services company E*Trade for dropping him from a new advertising campaign.

The actor, best known for roles in Pulp Fiction and Bad Lieutenant, was offered $1.5m (£950,000) to head up a set of three commercials for the company, but was later told the campaign was “moving in a different direction” and his services were no longer required. Keitel is claiming that E*Trade is in breach of contract and says the $150,000 termination fee they offered him isn’t enough.

According to the Hollywood Reporter, Keitel has filed a suit for the $1.5m fee, plus interest. In his legal documents, the actor said: “By offering a ‘kill fee’, E*Trade acknowledged and admitted that it had an existing, binding and enforceable contract with Mr Keitel.”

Keitel wasn’t the company’s first choice for the campaign. E*Trade made him an offer after Christopher Walken turned down the gig. But they reportedly had a change of heart and made one more appeal to Walken, who again said no. Keitel was once again offered the role, but two days after he accepted the deal, E*Trade told him he was no longer needed. Ultimately, their celebrity product hawker ended up being Kevin Spacey, who starred in ads such as the one below.

Watch Kevin Spacey in an ad for E*Trade – video

Keitel previously headed the Direct Line ads in the UK. He will next be seen in Paolo Sorrentino’s Youth and the Indian drama Gandhi of the Month.

Explore more on these topics

Comments (…)

Sign in or create your Guardian account to join the discussion

Most viewed

Most viewed